10-Q: Nu-Med Plus Reports Q3 2024 Results, Merger Agreement Terminated

Nu-Med Plus, Inc. reported its third quarter 2024 results, showing no revenue and a net loss, while also announcing the termination of its merger agreement with YourSpace America, Inc.

Summary

• Nu-Med Plus, Inc. reported no revenue for the three and nine months ended September 30, 2024.
• The company experienced a net loss of $18,677 for the three months ended September 30, 2024, and a net loss of $57,790 for the nine months ended September 30, 2024.
• Operating expenses were $17,417 for the three months and $54,037 for the nine months ended September 30, 2024.
• The company's cash balance was $4,041 as of September 30, 2024, down from $6,806 at the end of 2023.
• The merger agreement with YourSpace America, Inc. was terminated on October 28, 2024.
• The company has a working capital deficiency of $204,541 as of September 30, 2024.
• The company anticipates needing $1,200,000 in additional financing over the next twelve months to cover overhead and product development.
• The company's current funding is only sufficient through November 30, 2024.

Sentiment

Score: 2

Explanation: The document paints a very negative picture due to the lack of revenue, significant losses, termination of the merger agreement, and the company's precarious financial situation. The company's ability to continue as a going concern is in doubt.

Positives

• Operating expenses decreased for the nine months ended September 30, 2024, compared to the same period in 2023, primarily due to lower legal and rent expenses.
• The company has developed several nitric oxide delivery systems, including a hospital system, a clinical unit, and a mobile device, although these are not yet commercialized.

Negatives

• The company has no revenue and is experiencing significant net losses.
• The termination of the merger agreement with YourSpace America, Inc. is a setback.
• The company has a substantial working capital deficiency.
• The company's cash reserves are very low and will not sustain operations for long.
• The company is heavily reliant on external funding and has no assurance of obtaining it.
• The company's products are still in the development stage and require FDA approval before commercialization.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient funding.
• The company is dependent on a small group of investors for funding, and their inability or unwillingness to provide further capital could jeopardize the company's viability.
• The company faces significant challenges in obtaining FDA approval for its products, which is a lengthy and expensive process.
• The company's products are not yet commercialized and may not achieve market acceptance.
• The company's reliance on external funding exposes it to the risk of not securing sufficient capital at acceptable rates.
• The company's development of products has been suspended until further funding is received.

Future Outlook

The company anticipates needing $1,200,000 in additional financing over the next twelve months to cover overhead and product development, and has no assurance that it will be able to obtain this funding.

Management Comments

• Management believes that with the further refinement of our formulation, we can make and filter medical grade nitric oxide gas with minimal amounts of nitrogen dioxide.
• Management anticipates that selling our units earlier into the market as laboratory equipment or to international groups will pave the way for sales of our medical delivery devices.
• Management believes that there is ample room for a competitive response from NU-MED using on site generated nitric oxide at a lower cost to penetrate the market.

Industry Context

The company is operating in the medical device field, specifically focusing on nitric oxide delivery systems. The market for nitric oxide therapies is growing, but the company faces competition from established players and the need for regulatory approvals.

Comparison to Industry Standards

• The company's lack of revenue and significant losses are not uncommon for early-stage medical device companies, particularly those focused on novel therapies.
• The company's reliance on external funding is typical for companies in this sector, but the level of uncertainty regarding future funding is a concern.
• The company's development of multiple nitric oxide delivery systems is ambitious, but the lack of FDA approval and commercialization is a significant hurdle.
• The company's focus on reducing the cost of nitric oxide delivery could provide a competitive advantage if successful, as the current market is dominated by a single source with high prices.

Management Changes

Related Party Transactions

• The company has accounts payable to a related party totaling $74,479 as of September 30, 2024.

Stakeholder Impact

• Shareholders are at risk of losing their investment due to the company's financial difficulties.
• Employees may face job insecurity due to the company's uncertain future.
• The company's suppliers and creditors may face payment delays or defaults if the company's financial situation does not improve.

Next Steps

• The company needs to secure additional funding to continue operations and product development.
• The company needs to re-evaluate its strategic options following the termination of the merger agreement.
• The company needs to pursue FDA approval for its products once funding is secured.

Key Dates

Keywords

nitric oxide, medical device, FDA approval, merger, funding, financial results, going concern, share exchange agreement, capital raise, product development